Myriad Genetics (NASDAQ:MYGN - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.070-0.110 for the period, compared to the consensus earnings per share estimate of 0.090. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $883.1 million. Myriad Genetics also updated its FY25 guidance to $0.07-0.11 EPS.
Myriad Genetics Price Performance
Shares of MYGN traded down $0.53 during midday trading on Wednesday, reaching $13.15. The stock had a trading volume of 853,375 shares, compared to its average volume of 873,184. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -10.12 and a beta of 1.89. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. Myriad Genetics has a 12-month low of $12.81 and a 12-month high of $29.30. The company's 50-day moving average is $14.98 and its 200 day moving average is $22.10.
Wall Street Analysts Forecast Growth
Several research firms have commented on MYGN. StockNews.com raised shares of Myriad Genetics from a "hold" rating to a "buy" rating in a research note on Thursday, January 9th. UBS Group started coverage on shares of Myriad Genetics in a research report on Tuesday, December 10th. They set a "neutral" rating and a $18.00 price target for the company. Bank of America decreased their price objective on Myriad Genetics from $15.00 to $13.00 and set an "underperform" rating on the stock in a report on Friday, December 13th. Piper Sandler reduced their price target on Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating on the stock in a research report on Monday, November 11th. Finally, Morgan Stanley decreased their price target on Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Myriad Genetics currently has an average rating of "Hold" and a consensus target price of $24.27.
Read Our Latest Analysis on Myriad Genetics
Myriad Genetics Company Profile
(
Get Free Report)
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Recommended Stories
Before you consider Myriad Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.
While Myriad Genetics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
